Results 211 to 220 of about 18,027,656 (296)

Interplay between RNA‐protein interactions and RNA structures in gene regulation

FEBS Open Bio, EarlyView.
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko, Mauro Scaravilli, Minna‐Liisa Änkö   +2 more
wiley   +1 more source

The diagnostic efficiency of tissue factor pathway inhibitor 2 methylation in the detection of colorectal cancer: a systematic review and meta-analysis. [PDF]

J Gastrointest Oncol
Wang XL, Qin S, Liu L, Jia YQ, Wang Y, Zhou YJ, Ramos-Molina B, Valladares-Ayerbes M, Eidens M, Liu ZZ.   +9 more
europepmc   +1 more source

Tissue factor pathway inhibitor: structure-function.

Frontiers in Bioscience, 2012
G. Broze, T. Girard
semanticscholar   +1 more source

Tryptophan metabolite atlas uncovers organ, age, and sex‐specific variations

FEBS Open Bio, EarlyView.
Tryptophan metabolites were analyzed across twelve organs, the central nervous system, and serum in male and female mice at three life stages. We found tissue‐, sex‐, and age‐specific differences, including increased indole‐3‐pyruvate and kynurenine in aging males.
Lizbeth Perez‐Castro, Afshan F. Nawas, Jessica A. Kilgore, Pedro A. S. Nogueira, M.Carmen Lafita‐Navarro, Paul H. Acosta, Roy Garcia, Noelle S. Williams, Maralice Conacci‐Sorrell   +8 more
wiley   +1 more source

The impact of protein S and tissue factor pathway inhibitor on coagulation, assessed with thrombin generation, in women starting combined oral contraceptives. [PDF]

Res Pract Thromb Haemost
Strandberg J, Nybo J, Gade IL, Kristensen SR.   +3 more
europepmc   +1 more source

PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.

Blood, 2012
R. Kasthuri, Sam L. Glover, William Jonas, T. McEachron, R. Pawlinski, G. Arepally, N. Key, N. Mackman   +7 more
semanticscholar   +1 more source

Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival

FEBS Open Bio, EarlyView.
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel, Caroline Wozniak, Aya Sabri, Ben Haddad, Brooke Lopo, Alvaro Cobos, Sarah Sarofim, Jeffrey Guthrie, Deborah Heyl, Hedeel Guy Evans   +9 more
wiley   +1 more source

Tissue factor, factor VIII and IX in microvesicle-induced thrombosis and tumor growth of pancreatic cancer. [PDF]

Thromb J
Chou SC, Chang SL, Yu CY, Lin CI, Chang YT, Chen LF, Li JY, Pai CH, Lin SR, Cheng WC, Yuan CT, Lin SW.   +11 more
europepmc   +1 more source

Regulation of tissue factor coagulant activity on cell surfaces

Journal of Thrombosis and Haemostasis, 2012
L. Rao, U. Pendurthi
semanticscholar   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source